Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis

Ueno, Takehisa; Kodama, Tasuku; Noguchi, Yuki; Nomura, Motonari; Saka, Ryuta; Takama, Yuichi; Tazuke, Yuko; Bessho, Kazuhiko; Okuyama, Hiroomi

doi:https://doi.org/10.1007/s00383-019-04535-9

Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis

Ueno, Takehisa; Kodama, Tasuku; Noguchi, Yuki et al.

Pediatric Surgery International, 2019, 35(10), 1065-1070

Number of Access:1,115（2025-07-22 21:52 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/96480

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available
PediatrSurgInt_35_10_1065	pdf	None	315 KB	71	2024.07.01
PediatrSurgInt_35_10_1065_figure	pdf	None	133 KB	19	2024.07.01
PediatrSurgInt_35_10_1065_table	pdf	None	247 KB	22	2024.07.01

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis
Creator	NRID 1000010456957 1000010456957 ORCID 0000-0002-4639-8814 0000-0002-4639-8814 researchmap permalink ueno-pedsurg ueno-pedsurg Scopus Author ID 21743992300 21743992300 CreatorName Ueno, Takehisa
	NRID 1000060771045 1000060771045 CreatorName Kodama, Tasuku
	NRID 1000030771042 1000030771042 CreatorName Noguchi, Yuki
	NRID 1000040546909 1000040546909 researchmap permalink moto_pedsurg moto_pedsurg Scopus Author ID 35208741700 35208741700 ORCID 0009-0004-0959-7461 0009-0004-0959-7461 CreatorName Nomura, Motonari
	NRID 1000000459190 1000000459190 ORCID 0000-0001-8960-8618 0000-0001-8960-8618 researchmap permalink sakaryuta sakaryuta CreatorName Saka, Ryuta
	NRID 1000050467560 1000050467560 researchmap permalink tytyty_ytytyt tytyty_ytytyt CreatorName Takama, Yuichi
	NRID 1000010397698 1000010397698 researchmap permalink yukotazuke-osaka yukotazuke-osaka Scopus Author ID 7006109798 7006109798 ORCID 0000-0002-8335-0414 0000-0002-8335-0414 CreatorName Tazuke, Yuko
	NRID 1000080423169 1000080423169 researchmap permalink KazuBe KazuBe CreatorName Bessho, Kazuhiko
	NRID 1000030252670 1000030252670 researchmap permalink okuyamahiroomi okuyamahiroomi Scopus Author ID 35496082300 35496082300 ORCID 0000-0002-1347-282X 0000-0002-1347-282X CreatorName Okuyama, Hiroomi
Subject	Biliary atresia
	Child–Pugh score
	Liver fibrosis
	Mac-2-binding protein
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00383-019-04535-9
Abstract	Purpose: Biliary atresia (BA) is characterized by progressive liver fibrosis, but it is difficult to assess the progression after the patient develops cirrhosis. Mac-2-binding protein glycosylation isomer (M2BPGi) is a new marker for hepatic fibrosis. We examined the chronological changes in M2BPGi levels in BA patients with cirrhosis. Methods: Patients with cirrhosis were selected from among pediatric BA patients who had their native livers. Serum M2BPGi levels and Child–Pugh classification were evaluated. A total of 11 pediatric BA patients with cirrhosis were recruited. Results: Initial M2BPGi level after diagnosis of liver cirrhosis based on liver biopsy was on average 3.4, and the most recent M2BPGi level under observation was on average 4.3. The follow-up period from the initial M2BPGi measurement averaged 22.6 months. The ratio of the initial and most recent values (M2BPGi ratio) was on average 1.3 (0.5–2.4). Three cases with improved fibrosis (M2BPGi ratio < 1.0) remained in Child A, as did six cases (1.0 ≤ M2BPGi ratio < 2.0), but two cases with marked fibrosis progression (2.0 ≤ M2BPGi ratio) advanced to decompensated cirrhosis Child B. Conclusion: M2BPGi is useful as a prognostic factor for BA patients with liver cirrhosis. In addition, fibrosis improved even after the development of cirrhosis.
Publisher	Springer-Verlag GmbH.
Source Title	Pediatric Surgery International
Volume (Issue)	35(10)
Page	1065-1070
Date of Issued	2019-10-01
Language	English
Handle URL	https://hdl.handle.net/11094/96480
PISSN	01790358
eISSN	14379813
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s00383-019-04535-9
Access Rights	open access
CopyRight	© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCTERMS.bibliographicCitation	Pediatric Surgery International. 2019, 35(10), p. 1065-1070
DC.title	Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis
DC.creator	Ueno, Takehisa
	Kodama, Tasuku
	Noguchi, Yuki
	Nomura, Motonari
	Saka, Ryuta
	Takama, Yuichi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
DC.publisher	Springer-Verlag GmbH.
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2019-10-01
DC.identifier	https://doi.org/10.1007/s00383-019-04535-9
DC.subject	Biliary atresia
	Child–Pugh score
	Liver fibrosis
	Mac-2-binding protein
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00383-019-04535-9
DCTERMS.abstract	Purpose: Biliary atresia (BA) is characterized by progressive liver fibrosis, but it is difficult to assess the progression after the patient develops cirrhosis. Mac-2-binding protein glycosylation isomer (M2BPGi) is a new marker for hepatic fibrosis. We examined the chronological changes in M2BPGi levels in BA patients with cirrhosis. Methods: Patients with cirrhosis were selected from among pediatric BA patients who had their native livers. Serum M2BPGi levels and Child–Pugh classification were evaluated. A total of 11 pediatric BA patients with cirrhosis were recruited. Results: Initial M2BPGi level after diagnosis of liver cirrhosis based on liver biopsy was on average 3.4, and the most recent M2BPGi level under observation was on average 4.3. The follow-up period from the initial M2BPGi measurement averaged 22.6 months. The ratio of the initial and most recent values (M2BPGi ratio) was on average 1.3 (0.5–2.4). Three cases with improved fibrosis (M2BPGi ratio < 1.0) remained in Child A, as did six cases (1.0 ≤ M2BPGi ratio < 2.0), but two cases with marked fibrosis progression (2.0 ≤ M2BPGi ratio) advanced to decompensated cirrhosis Child B. Conclusion: M2BPGi is useful as a prognostic factor for BA patients with liver cirrhosis. In addition, fibrosis improved even after the development of cirrhosis.
DC.rights	© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
DC.format	96480
citation_title	Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis
citation_author	Ueno, Takehisa
	Kodama, Tasuku
	Noguchi, Yuki
	Nomura, Motonari
	Saka, Ryuta
	Takama, Yuichi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
citation_publisher	Springer-Verlag GmbH.
citation_language	English
citation_date	2019-10-01
citation_journal_title	Pediatric Surgery International
citation_volume	35
citation_issue	10
citation_firstpage	1065
citation_lastpage	1070
citation_doi	https://doi.org/10.1007/s00383-019-04535-9
citation_public_url	https://hdl.handle.net/11094/96480

Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis

Link to primary information

Item Information

Show details